Literature DB >> 17496165

A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.

Richard W Chapman1, Michael Minnicozzi, Chander S Celly, Jonathan E Phillips, Ted T Kung, R William Hipkin, Xuedong Fan, Diane Rindgen, Gregory Deno, Richard Bond, Waldemar Gonsiorek, Motasim M Billah, Jay S Fine, John A Hey.   

Abstract

Sch527123 [2-hydroxy-N,N-dimethyl-3-[[2-[[1(R)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]ben-zamide] is a potent, selective antagonist of the human CXCR1 and CXCR2 receptors (Gonsiorek et al., 2007). Here we describe its pharmacologic properties at rodent CXCR2 and at the CXCR1 and CXCR2 receptors in the cynomolgus monkey, as well as its in vivo activity in models demonstrating prominent pulmonary neutrophilia, goblet cell hyperplasia, and mucus production. Sch527123 bound with high affinity to the CXCR2 receptors of mouse (K(d) = 0.20 nM), rat (K(d) = 0.20 nM), and cynomolgus monkey (K(d) = 0.08 nM) and was a potent antagonist of CXCR2-mediated chemotaxis (IC(50) approximately 3-6 nM). In contrast, Sch527123 bound to cynomolgus CXCR1 with lesser affinity (K(d) = 41 nM) and weakly inhibited cynomolgus CXCR1-mediated chemotaxis (IC(50) approximately 1000 nM). Oral treatment with Sch527123 blocked pulmonary neutrophilia (ED(50) = 1.2 mg/kg) and goblet cell hyperplasia (32-38% inhibition at 1-3 mg/kg) in mice following the intranasal lipopolysaccharide (LPS) administration. In rats, Sch527123 suppressed the pulmonary neutrophilia (ED(50) = 1.8 mg/kg) and increase in bronchoalveolar lavage (BAL) mucin content (ED(50) =<0.1 mg/kg) induced by intratracheal (i.t.) LPS. Sch527123 also suppressed the pulmonary neutrophilia (ED(50) = 1.3 mg/kg), goblet cell hyperplasia (ED(50) = 0.7 mg/kg), and increase in BAL mucin content (ED(50) = <1 mg/kg) in rats after i.t. administration of vanadium pentoxide. In cynomolgus monkeys, Sch527123 reduced the pulmonary neutrophilia induced by repeat bronchoscopy and lavage (ED(50) = 0.3 mg/kg). Therefore, Sch527123 may offer benefit for the treatment of inflammatory lung disorders in which pulmonary neutrophilia and mucus hypersecretion are important components of the underlying disease pathology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17496165     DOI: 10.1124/jpet.106.119040

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  49 in total

Review 1.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 2.  New development in studies of formyl-peptide receptors: critical roles in host defense.

Authors:  Liangzhu Li; Keqiang Chen; Yi Xiang; Teizo Yoshimura; Shaobo Su; Jianwei Zhu; Xiu-wu Bian; Ji Ming Wang
Journal:  J Leukoc Biol       Date:  2015-12-23       Impact factor: 4.962

3.  Inhibition of neutrophil migration in mice by mouse formyl peptide receptors 1 and 2 dual agonist: indication of cross-desensitization in vivo.

Authors:  Yoshitaka Sogawa; Takao Ohyama; Hiroaki Maeda; Kazuki Hirahara
Journal:  Immunology       Date:  2010-10-29       Impact factor: 7.397

Review 4.  The mercurial nature of neutrophils: still an enigma in ARDS?

Authors:  Andrew E Williams; Rachel C Chambers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-12-06       Impact factor: 5.464

5.  Neutrophil accumulation and NET release contribute to thrombosis in HIT.

Authors:  Kandace Gollomp; Minna Kim; Ian Johnston; Vincent Hayes; John Welsh; Gowthami M Arepally; Mark Kahn; Michele P Lambert; Adam Cuker; Douglas B Cines; Lubica Rauova; M Anna Kowalska; Mortimer Poncz
Journal:  JCI Insight       Date:  2018-09-20

6.  Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infection.

Authors:  Wiebke Herbold; Regina Maus; Ines Hahn; Nadine Ding; Mrigank Srivastava; John W Christman; Matthias Mack; Jörg Reutershan; David E Briles; James C Paton; Christine Winter; Tobias Welte; Ulrich A Maus
Journal:  Infect Immun       Date:  2010-04-05       Impact factor: 3.441

Review 7.  Chemokine receptor antagonists: overcoming developmental hurdles.

Authors:  Richard Horuk
Journal:  Nat Rev Drug Discov       Date:  2008-12-12       Impact factor: 84.694

8.  Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.

Authors:  Seema Singh; Anguraj Sadanandam; Kalyan C Nannuru; Michelle L Varney; Rosemary Mayer-Ezell; Richard Bond; Rakesh K Singh
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

Review 9.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

10.  Vanadium pentoxide induces pulmonary inflammation and tumor promotion in a strain-dependent manner.

Authors:  Elizabeth A Rondini; Dianne M Walters; Alison K Bauer
Journal:  Part Fibre Toxicol       Date:  2010-04-12       Impact factor: 9.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.